Pharmaceuticals, Biotechnology and Life Sciences
St. Jude Children’s Research Hospital scientists in association with other researchers have worked out how a crucial cancer-related protein, a “histone writer” called Ezh2, plays a role in suppressing as well as driving the most aggressive form of the brain tumor medulloblastoma.
In vivo electroporation of intratumoral plasmid IL-12 (ImmunoPulse IL-12) enhances immunogenicity in poorly immunogenic mouse cancer models, said OncoSec Medical in a poster presentation in Canada.
Kaya Holdings got its third Marijuana Retailer license from the Oregon Liquor Control Commission (OLCC), and has opened its third Kaya Shack Retail Marijuana location.
Congressional Republicans recrafted their Obamacare replacement bill on Monday in hopes of satisfying critics as U.S. President Donald Trump prepared to promote his first major legislative initiative on Capitol Hill.
Allergan has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLLURETM XC, for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21.
Bristol-Myers Squibb and CytomX Therapeutics, a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, have expanded their 2014 strategic collaboration to discover novel therapies that will include up to eight additional targets using CytomX’s proprietary Probody platform.
Eli Lilly’s phase 3 double-blind study (MONARCH 2) designed to evaluate the efficacy and safety of abemaciclib, in combination with fulvestrant, in patients with advanced (locoregionally recurrent or metastatic) breast cancer has met its primary endpoint.
Array BioPharma said on Sunday it has exited the U.S. Food and Drug Administration’s (FDA) Division of Oncology Products 2 its new drug application (NDA) for binimetinib monotherapy for the treatment of NRAS-mutant melanoma, a rare, mutationally-driven subset of skin cancer.
AstraZeneca’s subsidiary ZS Pharma has been developing an oral powder as a treatment for high potassium levels in the blood serum, called hyperkalaemia, for which it got a Complete Response Letter (CRL) from the Food and Drug Administration (FDA).
Diplomat Pharmacy will distribute Novartis’s newly approved breast cancer drug Kisqali (ribociclib) as a first-line treatment for postmenopausal women with a serious form of the disease.